 "Aurobindo Pharma wrests second position among drug firms from Lupin")
Shares of Aurobindo Pharma slipped 5 per cent to Rs 684.50 on the BSE in Friday’s intra-day trade after the company said the has received a warning letter from the US Food and Drug Administration (USFDA) for its Unit I, an active pharmaceutical ingredient (API) manufacturing facility in Hyderabad.
At 12:30 pm; the stock traded 4 per cent lower at Rs 690, as compared to 0.40 per cent decline on the S&P BSE Sensex. The stock had hit a 52-week low of Rs 620.55 on November 11, 2021. The trading volume at the counter jumped over four-fold with a
At 12:30 pm; the stock traded 4 per cent lower at Rs 690, as compared to 0.40 per cent decline on the S&P BSE Sensex. The stock had hit a 52-week low of Rs 620.55 on November 11, 2021. The trading volume at the counter jumped over four-fold with a
